Go to
current issue
-
Molecular epigenomic subtypes of Barrett neoplasia Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-25 Stephen J. Meltzer
Genomic alterations are well-described in Barrett oesophagus and its sequela, oesophageal adenocarcinoma, but epigenomic events have not been so widely investigated. In a new study, Jammula et al. analysed the DNA methylation profiles of Barrett oesophagus, oesophageal adenocarcinoma and control tissues. Four molecular subtypes were identified, revealing four distinct epigenomic classes and potential
-
Management of IBD during the COVID-19 outbreak: resetting clinical priorities Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-25 Silvio Danese; Maurizio Cecconi; Antonino Spinelli
-
COVID-19: faecal–oral transmission? Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-25 Jordan Hindson
-
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-19 Azucena Salas; Cristian Hernandez-Rocha; Marjolijn Duijvestein; William Faubion; Dermot McGovern; Severine Vermeire; Stefania Vetrano; Niels Vande Casteele
-
Mitochondrial dysfunction in Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-17 Katrina Ray
-
Social media and medicine Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-12 Austin L. Chiang
-
The multidisciplinary management of rectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-12 Deborah S. Keller; Mariana Berho; Rodrigo O. Perez; Steven D. Wexner; Manish Chand
-
Brassica vegetable metabolism by gut microbiota Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-11 Jordan Hindson
-
Publisher Correction: Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-11 Bin Chen; Lana Garmire; Diego F. Calvisi; Mei-Sze Chua; Robin K. Kelley; Xin Chen
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-09 Nick J. Spencer; Hongzhen Hu
-
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-09 Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G. Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
-
Evidence-based and mechanistic insights into exclusion diets for IBS. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-02 Paul Moayyedi,Magnus Simrén,Premysl Bercik
-
Mimicking coeliac disease in mice. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-03-02 Katrina Ray
-
Bridging transplantation with beads in paediatric acute liver failure. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-27 Patrick J McKiernan,Robert H Squires
-
Faecal microbiota transplantation in IBS - new evidence for success? Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-27 Julia König,Robert Jan Brummer
Faecal microbiota transplantation (FMT) aims to restore an altered microbiota and has been suggested as a potential treatment option for irritable bowel syndrome (IBS), among other diseases. A new study suggests that the use of a so-called superdonor is necessary to successfully treat patients with IBS using FMT.
-
Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-26 Juan F Burgueño,Maria T Abreu
-
New markers and models of premalignancy and the early development of gastric cancer. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-26 Katrina Ray
-
Enteric neuron regulation of gut motility by the microbiota. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-26 Jordan Hindson
-
Organoid models of gastrointestinal cancers in basic and translational research. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-25 Harry Cheuk Hay Lau,Onno Kranenburg,Haipeng Xiao,Jun Yu
-
Early-onset colorectal cancer: initial clues and current views. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-21 Lorne J Hofseth,James R Hebert,Anindya Chanda,Hexin Chen,Bryan L Love,Maria M Pena,E Angela Murphy,Mathew Sajish,Amit Sheth,Phillip J Buckhaults,Franklin G Berger
-
A trial of deep-learning detection in colonoscopy. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-21 Iain Dickson
-
H. pylori elimination reduces gastric cancer risk. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-21 Iain Dickson
-
FAST identification of NASH progression. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-21 Iain Dickson
-
Perioperative cetuximab plus chemotherapy reduces overall survival in metastatic disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-21 Iain Dickson
-
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-19 Aonghus Lavelle,Harry Sokol
-
Antidepressants in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-18 Antonina Mikocka-Walus,Alexander C Ford,Douglas A Drossman
-
Anti-tumorigenic endogenous gut bacteria in mice and humans. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-17 Jordan Hindson
-
Pancreatitis: a loss of FGF21 function disease with potential for correction. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-06 Iain Dickson
-
Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-03 Chih-Wei Ko,Jie Qu,Dennis D Black,Patrick Tso
-
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-31 Louis Buscail,Barbara Bournet,Pierre Cordelier
-
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-31 Amy M Buckley,Niamh Lynam-Lennon,Hazel O'Neill,Jacintha O'Sullivan
-
Collagen-targeted MRI contrast agent for liver fibrosis detection. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-24 Paul Kennedy,Bachir Taouli
-
Therapy-induced senescence - an induced synthetic lethality in liver cancer? Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-21 Katharina Wolter,Lars Zender
-
Shining a spotlight on somatic mutations in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-21 Katrina Ray
-
A new model of intestinal epithelial regeneration: could patients benefit? Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-20 Isabella Dotti,Azucena Salas
-
New approaches in viraemic organ transplantation and antiviral therapies. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-08 Jacinta A Holmes,Raymond T Chung
-
Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-03 Bin Chen,Lana Garmire,Diego F Calvisi,Mei-Sze Chua,Robin K Kelley,Xin Chen
-
Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-03 Gerhard Jung,Eva Hernández-Illán,Leticia Moreira,Francesc Balaguer,Ajay Goel
-
Balancing the risks and rewards of live biotherapeutics. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-23 Colin Hill
Live biotherapeutics have been used clinically both as defined probiotics and as undefined faecal microbiota transplants. Two new studies illustrate the risks of administering live microorganisms to highly compromised patients. These risks should be considered in the context of the potential therapeutic value of these treatments.
-
A role for nociceptor neurons in gut defence. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-23 Iain Dickson
-
High-definition medicine: modelling NAFLD in 3D. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-19 Katrina Ray
-
Host-microbiota interactions in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-17 Markus F Neurath
-
Deep-learning AI for neoplasia detection in Barrett oesophagus. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Iain Dickson
-
Mechanosensing of food in the gut. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Jordan Hindson
-
Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-09 Aliya F Gulamhusein,Gideon M Hirschfield
-
Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-06 Ryan M Thomas,Christian Jobin
-
An increasingly complex view of intestinal motility. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Meenakshi Rao
-
Tumour evolution in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-02 Amanda J Craig,Johann von Felden,Teresa Garcia-Lezana,Samantha Sarcognato,Augusto Villanueva
-
Manipulating the gut microbiota to combat alcoholic hepatitis. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-01 Katrina Ray
-
Big data and tiny proteins: shining a light on the dark corners of the gut microbiome. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Suzanne Devkota
-
Multispecies liver-on-a-chip for improved drug toxicity testing. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-01 Iain Dickson
-
Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-11-25 Jonathan L Digby-Bell,Raja Atreya,Giovanni Monteleone,Nick Powell
IBD treatment is undergoing a transformation with an expanding repertoire of drugs targeting different aspects of the immune response. Three novel classes of drugs have emerged in the past decade that target leukocyte trafficking to the gut (vedolizumab), neutralize key cytokines with antibodies (ustekinumab) and inhibit cytokine signalling pathways (tofacitinib). In advanced development are other
-
What's new in NAFLD pathogenesis, biomarkers and treatment? Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Christopher D Byrne,Giovanni Targher
-
Mapping the cells in the liver — unchartered subtypes and heterogeneity Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-07-30 Katrina Ray
-
Microbiota supplements to improve metabolic health Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-07-23 Anna Kriebs
-
Joining the dots for better liver cancer treatment. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-02-01 Lo-Kong Chan,Irene Oi-Lin Ng
-
Management of functional constipation in children and adults. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-11-05 Mana H Vriesman,Ilan J N Koppen,Michael Camilleri,Carlo Di Lorenzo,Marc A Benninga
-
Hepatocyte-stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-01 Josepmaria Argemi,Ramon Bataller
-
Diet linked to post-resection colorectal cancer recurrence. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2020-01-01 Jordan Hindson
-
PD-1 inhibitors for oesophageal cancer. Nat. Rev. Gastroenterol. Hepatol. (IF 23.57) Pub Date : 2019-12-01 Isobel Leake
Contents have been reproduced by permission of the publishers.
全部期刊列表>>
友情链接：
京公网安备 11010802027423号